Novo Nordisk (NVO) announced on Thursday that the U.K. drug regulator, the Medicines and Healthcare Products Regulatory Agency, approved its oral GLP-1 therapy, the Wegovy pill, for obese or overweight adults.

Therefore, the once-daily therapy will be marketed in the U.K. as